Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

32%

8 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed with results

Key Signals

91% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (5)
P 1 (6)
P 2 (5)
P 3 (3)
P 4 (5)

Trial Status

Completed10
Recruiting8
Unknown6
Terminated1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT06462196Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT06511908Phase 2Recruiting

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT07122193Phase 3Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07210463Phase 3Recruiting

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT06535568Not ApplicableRecruiting

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT04289142Phase 4Recruiting

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

NCT04572451Phase 1Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT05465031Phase 4Recruiting

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

NCT03646292Phase 4Completed

Antidiabetic Drugs for Steatotic Liver Disease

NCT05657860Phase 4Completed

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT04518852Phase 2Completed

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

NCT05321602Phase 1Completed

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT04922593Phase 1Completed

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT03572790Not ApplicableCompletedPrimary

Effects of Seven Day Prucalopride Administration in Healthy Volunteers

NCT04489420Phase 1Terminated

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

NCT05375240Phase 2Unknown

Propranolol on Post Stroke Immune Status and Infection

NCT03841292Not ApplicableCompleted

Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence

NCT04556071Phase 2Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

NCT04161404Phase 1Unknown

Pharmacometabolomics of Andrographis Paniculata And Metformin In Healthy Volunteers Under Fasting Condition

NCT04169230Not ApplicableUnknownPrimary

Citalopram and Self Emotional Processing

Scroll to load more

Research Network

Activity Timeline